INBX
NASDAQ
US
Inhibrx Biosciences, Inc. - Common Stock
$63.53
▼ $-3.52
(-5.25%)
Vol 190K
3
Quality Score
fail
Rev ✗
NI ✗
>IPO ✗
Mkt Cap
$1.1B
ROE
-140.3%
Margin
-5465.6%
D/E
271.29
Beta
2.35
52W
$11–$95
Wall Street Consensus
6 analysts · Apr 20260
Strong Buy
0
Buy
3
Hold
1
Sell
2
Strong Sell
0.0%
Buy Rating
Price Chart
Similar Stocks
CTMX
CytomX Therapeutics Inc
P/E 25.8
$721.8M
CMPX
Compass Therapeutics Inc.
$955.1M
AKTS
Aktis Oncology Inc
CDNA
CareDx Inc
P/E 15.9
$969.0M
JANX
Janux Therapeutics Inc
$830.0M
MPLT
MapLight Therapeutics Inc
$797.0M
ORIC
Oric Pharmaceuticals Inc
$796.6M
XNCR
Xencor Inc
$1.1B
ABUS
Arbutus Biopharma Corp
$925.1M
Earnings
Beat rate: 60.0%
Next Report
May 12, 2026
EPS Estimate: $-1.23
| Quarter | EPS Est | EPS Act | Surprise |
|---|---|---|---|
| Mar 2026 | $-1.23 | — | — |
| Dec 2025 | $-2.12 | $-2.11 | +$0.01 |
| Sep 2025 | $-1.75 | $-2.28 | $-0.53 |
| Jun 2025 | $-2.82 | $-1.85 | +$0.97 |
Fundamentals Trend
| Metric | 2025-06-30 | 2025-09-02 | 2025-10-02 | 2025-11-03 | 2025-12-03 | 2026-01-02 |
|---|---|---|---|---|---|---|
| ROE (TTM) | -94.9% | -94.9% | -94.9% | -94.9% | -94.9% | -140.3% |
| P/E (TTM) | — | — | — | — | — | — |
| Net Margin | -2204.2% | -5465.6% | -5465.6% | -5465.6% | -5465.6% | -5465.6% |
| Gross Margin | — | — | — | — | — | — |
| D/E Ratio | 144.81 | 144.81 | 144.81 | 144.81 | 144.81 | 271.29 |
| Current Ratio | 4.98 | 4.98 | 4.98 | 4.98 | 4.98 | 4.49 |
Key Ratios
ROA (TTM)
-58.8%
P/S (TTM)
820.68
P/B
1.7
EPS (TTM)
$-7.22
CF/Share
$-4.22
Rev Growth 3Y
-69.8%
52W High
$94.57
52W Low
$10.81
$10.81
52-Week Range
$94.57
How does INBX compare to Biotechnology peers?
Peer group: Micro-cap Biotechnology (All) · 528 companies
INBX valuation vs Biotechnology peers
P/E ratio
—
▼
0%
below
peers
(18.8)
vs Peers
vs Industry
Undervalued
P/S ratio
820.7
▲
6287%
above
peers
(12.9)
vs Peers
vs Industry
Overvalued
P/B ratio
1.7
▼
32%
below
peers
(2.5)
vs Peers
vs Industry
Pricier
Div yield
—
▼
0%
below
peers
(0.0%)
vs Peers
vs Industry
Low yield
INBX profitability vs Biotechnology peers
ROE
-140.3%
▼
108%
below
peers
(-67.3%)
vs Peers
vs Industry
Weak
Net margin
-5465.6%
▼
1806%
below
peers
(-286.8%)
vs Peers
vs Industry
Weak
Gross margin
—
▼
0%
below
peers
(78.6%)
vs Peers
vs Industry
In line
ROA
-58.8%
▼
26%
below
peers
(-46.7%)
vs Peers
vs Industry
Below avg
INBX financial health vs Biotechnology peers
D/E ratio
271.3
▼
0%
below
peers
(0.0)
vs Peers
vs Industry
High debt
Current ratio
4.5
▲
1%
above
peers
(4.4)
vs Peers
vs Industry
In line
Beta
2.4
▲
142%
above
peers
(1.0)
vs Peers
vs Industry
More volatile
INBX fundamentals radar
INBX
Peer median
Industry
INBX profitability vs leverage
Bubble size = market cap · X = net margin · Y = D/E ratio
INBX vs peers: key metrics
Latest News
No related news yet